ROGERS CORP
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $810.8 | $830.1 | $908.4 | $971.2 | $932.9 |
| Operating income | -$45.0 | $24.9 | $85.3 | $144.4 | $117.2 |
| Net income | -$61.8 | $26.1 | $56.6 | $116.6 | $108.1 |
| Cash Flow Statement | |||||
| Free cash flow | $71.1 | $71.0 | $74.4 | $12.7 | $53.3 |
| Share repurchases | $52.4 | $19.8 | $0.0 | $25.0 | $0.0 |
Shares outstanding 17.9M · Free float 95.6%
Annual filing data through FY ended December 31, 2025; float as of September 17, 2026.
Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
Roche and Zealand advance petrelintide’s amylin approach to obesity
September 23, 2026
Drug Pipeline
Roche and Zealand plan a two-mechanism obesity combination trial
September 23, 2026
Drug Pipeline
Lilly and Novo set the backdrop for a changing obesity pipeline
September 23, 2026
Drug Pipeline
Roche’s enicepatide adds diabetes results as Phase 3 trials recruit